Published in final edited form as:

Cancer Chemother Pharmacol. 2007 February ; 59(3): 369–374. doi:10.1007/s00280-006-0278-6.

Cisplatin's tumoricidal effect on human breast carcinoma MCF-7 cells was not attenuated by American ginseng

Han H. Aung, Sangeeta R. Mehendale, Chong Zhi Wang, Jing-Tian Xie, and Eryn McEntee
Tang Center for Herbal Medicine Research, The Pritzker School of Medicine, University of Chicago,
5841 S. Maryland Avenue, MC 4028, Chicago, IL 60637, USA

Department of Anesthesia and Critical Care, The Pritzker School of Medicine, University of Chicago,
Chicago, IL 60637, USA

Chun-Su Yuan

Tang Center for Herbal Medicine Research, The Pritzker School of Medicine, University of Chicago,
5841 S. Maryland Avenue, MC 4028, Chicago, IL 60637, USA

Department of Anesthesia and Critical Care, The Pritzker School of Medicine, University of Chicago,
Chicago, IL 60637, USA

Committee on Clinical Pharmacology and Pharmacogenomics, The Pritzker School of Medicine,
University of Chicago, Chicago, IL 60637, USA

Yuan Cancer Research Center, The Pritzker School of Medicine, University of Chicago, Chicago,
IL 60637, USA

Abstract

Purpose—We previously observed that American ginseng berry and ginsenoside Re attenuated cisplatin-induced emesis in a rat model, suggesting that the herb may have a value in treating chemotherapy-induced nausea/vomiting. However, it is not clear whether consuming ginseng concurrently with chemotherapy affects the efficacy of chemotherapeutic agents. In this study, we explored if the ginseng extract and its constituents, ginsenosides Rb₁, Rb₃, and Re, alter tumoricidal activity of cisplatin in human cancer cells.

Methods—Tumoricidal effects of cisplatin, and/or American ginseng berry extract (AGBE) and ginsenosides Rb₁, Rb₃, and Re, on human breast carcinoma MCF-7 cells were measured as cell proliferation in vitro. Cell counts were performed in MCF-7 cells pre-treated with test agents for 72 h.

Results—Cisplatin decreased MCF-7 cell proliferation significantly in a concentration-dependent manner. Compared to control group, cisplatin reduced the cell proliferations to 56.5±3.3% at 1 µg/ml, to 36.6±2.4% at 5 µg/ml, and to 26.9±2.4% at 15 µg/ml ($P<0.01$). AGBE also inhibited the cell proliferation significantly, although in a less extended manner. When the berry extract at 0.5 mg/ml was used with cisplatin at 1 µg/ml, a significant enhancement of cisplatin's activity was observed (35.8±2.5%; $P<0.05$). We also observed that Rb₁ did not change cisplatin's activity; Rb₃, at a higher concentration, increased cisplatin's anti-proliferation activity (48.0±1.2%; $P<0.05$); Re increased cisplatin's activity (Re 0.1 mg/ml, 48.0±2.8%; Re 0.3 mg/ml, 31.9±2.2%, $P<0.01$).

Conclusion—Our data suggest that AGBE and the tested ginsenosides do not attenuate cisplatin's tumoricidal activity in MCF-7 cells, but in fact may actually enhance it. Additionally, the ginseng extract and ginsenoside Re by themselves exerted anti-proliferative activity against MCF-7 cells.

The herb *might potentially* serve a complementary role with the chemotherapeutic agents in treating cancer, in addition to decreasing chemotherapy-induced nausea/vomiting.

Keywords

American ginseng berry; Ginsenoside Rb₁; Ginsenoside Rb₃; Ginsenoside Re; Cisplatin; Herbal–drug interaction; Breast carcinoma MCF-7 cell

Introduction

Treatment of cancer with chemotherapeutic agents such as cisplatin is associated with severe adverse effects. The drug-related adverse events not only worsen patients' quality of life but can also lead to their refusal to continue the potentially curative chemotherapy [20,27]. Nausea/vomiting is one of the most significant adverse effects of chemotherapy [27]. It is vital to adequately control this drug-induced symptom and the anticipatory emesis of subsequent chemotherapy cycles [27]. The currently available anti-emetic drugs can relieve the symptoms especially when used in combinations, but lead to the possibility of additional adverse events and potential drug–drug interactions causing a reduction in the efficacy of chemotherapeutic agents [12,32,33]. Recently, we reported that the berry extract of American ginseng (*Panax quinquefolius* L.) and its major constituent, ginsenoside Re, attenuated cisplatin-induced emesis in a rat model, and demonstrated the potential value of the herb in treating chemotherapy-induced nausea/vomiting [21]. Patients with cancer often resort to complementary and alternative medical means to treat the side effects of chemotherapy [24]. It therefore appears that American ginseng berry extract (AGBE) may have a clinical utility in this setting.

As an anti-oxidant herb, ginseng's effect on cisplatin-induced adverse effects could be linked to its anti-oxidant activity [13,21,30]. However, to date, it is not clear if consuming anti-oxidants concurrently with chemotherapy hampers or helps the tumoricidal activity of chemotherapeutic agents [14]. In this study, we evaluated whether American ginseng extract and its active constituents, ginsenosides Rb₁, Rb₃, and Re, alter tumoricidal activity of cisplatin in human breast carcinoma MCF-7 cells [25], which are sensitive to cisplatin.

Materials and methods

Preparation and analysis of AGBE

American ginseng berry (Wisconsin Ginseng Board, Wausau, WI, USA) was cultivated under standard conditions. The dried berry, obtained from a single batch, was ground into fine powder, dispersed in 75% ethanol, sonicated and refluxed for 1 h at 50°C [28]. The extraction procedure was repeated three times. The cooled mixture was filtered through Whatman No. 1 paper (Maidstone, England) and the filtrate was collected. The final residue was washed with ethanol and the solution was combined with the extract. The ethanol extract was dried under vacuum with rotary evaporator R-205 (Buchi Labortechnik AG, Flawil, Schweiz), dissolved in water, and extracted with water-saturated butanol (three times). The butanol layers were combined, washed with water, evaporated under vacuum, and freeze-dried.

High-performance liquid chromatography (HPLC) was conducted to confirm the ginsenoside profile of the AGBE using a Liquid Chromatography System of Waters model 2960 (Milford, MA, USA), with a quaternary pump, automatic injector, a 996 photodiode array detector, and Waters Millennium³² software for peak identification and integration. Ginsenosides were separated on a Phenomenex Prodigy ODS (2), 5 µm, 150×3.2 mm analytical column (Phenomenex, Torrance, CA, USA) [34,35]. The separation of ginsenosides was obtained at room temperature by gradient elution using acetonitrile (A) and water (B) as eluents. Gradient

elution started with 20% solvent A and 80% solvent B, changed to 20.3% A for 25 min, then changed to 26.8% A for 3 min and held for 26 min; changed to 35.6% A for 20 min; changed to 50% A for 11 min; changed to 68% A for 10 min; changed to 95% A for 1 min and held for 3 min; changed to 20% A for 3 min and held for 8 min. The absorbance was measured at 202 nm using the photodiode array detector. Figure 1 shows a chromatogram of AGBE assayed by HPLC, and three selected ginsenosides in AGBE.

Ginsenosides Rb₁ and Re, with purity of >98%, were obtained from Indofine Chemical Company (Somerville, NJ, USA). Ginsenoside Rb₃, with purity of >95%, was obtained from Delta Information Center for Natural Organic Compounds (Xuancheng, China).

Cell and culture conditions

The human breast carcinoma MCF-7 cells (ATCC, Manassas, VA, USA) were routinely grown in Dulbecco's modification of Eagle's minimal essential medium (DMEM), supplemented with 10% fetal bovine serum and penicillin-streptomycin (50 unit/ml; Invitrogen, Carlsbad, CA, USA). Cells were maintained in a tissue culture dish (100 mm in diameter) and kept in a humidified incubator (5% CO₂ in air at 37°C). Medium was changed every 2–3 days. When the cells reached 80–90% confluence, they were trypsinized, harvested, and seeded into a new tissue culture dish [6,15,19].

Cell proliferation assay

To examine the anti-proliferative effect of the test agents, MCF-7 cells were seeded in a 24-well plate at approximately 10,000 cells/well with regular DMEM medium and allowed to adhere for 24 h. After adhesion of MCF-7 cells, the culture medium was changed prior to the addition of drugs. The MCF-7 cells were incubated with testing material at various concentrations for 72 h. Control cultures were incubated in medium alone. At the end of treatments, MCF-7 cells were detached using trypsin and counted using a Coulter Counter (Coulter Electronics, Hialeah, FL, USA) [5,7]. On selected days after the removal of the incubation medium, the cell monolayer was washed twice with phosphate buffered saline. All assays were performed at least three times. The percentage of MCF-7 carcinoma cell proliferation was calculated as follows: cell proliferation (%) = 100 × (cell number in experimental well/cell number in the control well).

Statistical analysis

Data are expressed as mean ± standard error. Statistical analysis was performed using analysis of variance followed by a post hoc test for comparison of means. Differences were considered significant if $P < 0.05$.

Results

Tumoricidal effect of cisplatin on MCF-7 carcinoma cells

The tumoricidal activity of cisplatin on MCF-7 carcinoma cells is shown in Fig. 2. Cisplatin decreased MCF-7 carcinoma cell proliferation significantly in a concentration-dependent manner. Compared to control group (100%), cisplatin reduced the cell proliferations to 56.5 ± 3.3% at 1 µg/ml, to 36.6 ± 2.4% at 5 µg/ml, and to 26.9 ± 2.4% at 15 µg/ml ($P < 0.01$). Cisplatin at a dose of 1 µg/ml was selected for studying the interaction between cisplatin and ginseng.

Figure 2 also shows the effects of AGBE on MCF-7 cells. AGBE inhibited the cell proliferation significantly as well, although in a less extended manner. Compared to control group, AGBE reduced the cell proliferations to 90.4 ± 3.6% at 0.1 mg/ml, and to 66.7 ± 3.0% at 0.5 mg/ml ($P < 0.01$).

Effect of AGBE on cisplatin's tumoricidal activity

As shown in Fig. 3, compared to cisplatin alone at 1 $\mu\text{g/ml}$ ($56.5 \pm 3.3\%$), cisplatin at 1 $\mu\text{g/ml}$ plus AGBE at 0.1 mg/ml elicited an increasing trend in anti-proliferation activity ($49.1 \pm 3.2\%$). When AGBE at 0.5 mg/ml was used with the same concentration of cisplatin, a significant change was observed ($35.8 \pm 2.5\%$; $P < 0.05$ compared to cisplatin alone). These data suggest that AGBE does not attenuate cisplatin's tumoricidal activity. Rather, at a concentration of 0.5 mg/ml, AGBE enhanced the tumoricidal activity of cisplatin on MCF-7 cells.

Interaction between cisplatin and ginsenosides on MCF-7 carcinoma cells

To explore which ginsenosides in AGBE play a major role in the additive effects of cisplatin's tumoricidal activity, three ginsenosides were tested (Fig. 4). While, ginsenoside Rb₁ did not change cisplatin's activity significantly, ginsenoside Rb₃, at a higher concentration, increased cisplatin's activity (48.0 ± 1.2 ; $P < 0.05$). We also observed that ginsenoside Re increased cisplatin's activity in a concentration-related manner (Re 0.1 mg/ml, 48.0 ± 2.8 ; Re 0.3 mg/ml, 31.9 ± 2.2 , $P < 0.01$).

Discussion

Ginseng has been used for centuries in Oriental countries as a panacea that promotes longevity [2,11,17], and is considered reasonably safe [8]. There are mainly two different kinds of ginseng based on their geographical location of cultivation, i.e., Asian ginseng and American ginseng. Both of them show comparable properties of restoring and enhancing normal well-being and are thereby collectively known as adaptogens [2,11,17]. In this study, we used American ginseng, one of the most commonly consumed herbs in the United States [3]. The berry of ginseng, which was reported in our previous investigation as reducing chemotherapy-induced nausea/vomiting [21], was used in this study. We have also previously demonstrated that the berry has a significantly higher content of total ginsenosides than the root of ginseng [35].

In our previous study, an anti-emetic effect of AGBE was observed using a cisplatin-induced rat model, and our data suggest that this effect was mediated through the extract's anti-oxidant activity [21]. Clinically, specific beneficial effects such as anti-ischemic, anti-hypertensive and *immune modulating effects* have been attributed to the use of ginseng [16,30]. These pharmacological effects are, to a significant extent, also considered to be due to the anti-oxidant properties of the herb [22]. Kitts et al. reported that American ginseng exhibited effective anti-oxidant activity in both lipid-soluble and water-soluble medium by chelating metal ions and through the direct scavenging of DPPH and hydroxyl radicals in an in vitro study [13]. In addition to anti-oxidant properties, American ginseng also stimulates NO (nitric oxide) release, which could modulate the anti-oxidant activity [11].

The mechanism of tumoricidal action of cisplatin is similar to that of the alkylating group of drugs and is achieved through DNA cross-linking [37]. Thus, the chemotherapeutic activity of cisplatin is not mainly mediated through oxygen radical generation. However, oxygen radical production is a significant adverse event *that occurs* with cisplatin treatment and results in tissue injury [26,29,36]. Administering anti-oxidants could treat the oxidant-mediated side effects but might have possible interactions with the tumoricidal actions of cisplatin [14]. Interactions of cisplatin with the anti-oxidant, *N*-acetyl cysteine, demonstrated an inhibition of anti-tumor activity [14]. On the contrary, other anti-oxidants, such as quercetin and glutathione, showed a trend towards greater tumor response or anti-tumor activity [1,14]. Other investigators have shown that anti-oxidant treatment could help to prevent gastrointestinal toxicity, nephrotoxicity, and ototoxicity, without affecting the anti-cancer activity [4,36]. L-Carnitine prevented cisplatin-induced oxidant injury of the kidneys and intestines while preserving cisplatin's tumoricidal activity in a rat model [4]. It thus appears that the outcomes

of interaction between cisplatin and anti-oxidants depend on the specific anti-oxidants. Since the anti-proliferative activity of ginseng in MCF-7 cells appears to be mediated by arresting cell cycle, it should not interfere with cisplatin's anti-tumor activity [23]. In the present study, we observed that the interaction between ginseng and cisplatin is complementary.

Ginsenosides are active constituents in ginseng [2], and some ginsenosides have individually exhibited anti-oxidant properties [10,18]. Ginseng root has a relatively high content of Rb₁ compared to that of ginseng berry, while the berry has significantly higher contents of Rb₃ and Re [31]. Corbit et al. recently observed an anti-proliferative effect of American ginseng root on MCF-7 cells [9]. In this study, the effects of AGBE and selected ginsenosides on cisplatin's tumoricidal activity were individually tested in the MCF-7 cell line. Our data showed that Re has a significant additive effect on cisplatin's activity, and that Re could be responsible for the ginseng berry's positive interaction with cisplatin.

Cisplatin is used extensively as an effective chemotherapeutic agent in treating a variety of cancers. Our data demonstrated that the ginseng berry extract and Re possess tumoricidal activity and contribute an additive effect to cisplatin's activity. The anti-cancer effect of ginseng increases the likelihood that the anti-oxidant herb might serve a complementary role with the chemotherapeutic agents in treating cancer, in addition to potentially decreasing chemotherapy-induced nausea/vomiting. Cancer patients are known to use herbal products more often than the general populace [24], and thus, well-investigated herbal therapies can offer patients with a practical alternative.

Acknowledgments

This work was supported in part by the NIH/NCCAM grants AT002176 and AT002445.

References

1. Akbas SH, Timur M, Ozben T. The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells. *J Surg Res* 2005;125:49–55. [PubMed: 15836850]
2. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. *Biochem Pharmacol* 1999;58:1685–1693. [PubMed: 10571242]
3. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. *Adv Data* 2004;343:1–19. [PubMed: 15188733]
4. Chang B, Nishikawa M, Sato E, Utsumi K, Inoue M. L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. *Arch Biochem Biophys* 2002;405:55–64. [PubMed: 12176057]
5. Chang JS, Chiang LC, Hsu FF, Lin CC. Chemoprevention against hepatocellular carcinoma of *Cornus officinalis* in vitro. *Am J Chin Med* 2004;32:717–725. [PubMed: 15633807]
6. Choi SH, Im E, Kang HK, Lee JH, Kwak HS, Bae YT, Park HJ, Kim ND. Inhibitory effects of costunolide on the telomerase activity in human breast carcinoma cells. *Cancer Lett* 2005;227:153–162. [PubMed: 16112418]
7. Colston KW, Perks CM, Xie SP, Holly JM. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. *J Mol Endocrinol* 1998;20:157–162. [PubMed: 9513092]
8. Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. *Drug Saf* 2002;25:323–344. [PubMed: 12020172]
9. Corbit R, Ebbs S, King ML, Murphy LL. The influence of lead and arsenite on the inhibition of human breast cancer MCF-7 cell proliferation by American ginseng root (*Panax quinquefolius* L.). *Life Sci* 2006;78:1336–1340. [PubMed: 16288926]
10. Deng HL, Zhang JT. Anti-lipid peroxidative effect of ginsenoside Rb₁ and Rg₁. *Chin Med J (Engl)* 1991;104:395–398. [PubMed: 1879209]
11. Gillis CN. Panax ginseng pharmacology: a nitric oxide link? *Biochem Pharmacol* 1997;54:1–8. [PubMed: 9296344]

12. Herrstedt J. Antiemetic research: a look to the future. *Support Care Cancer* 1998;6:8–12. [PubMed: 9458530]
13. Kitts D, Hu C. Efficacy and safety of ginseng. *Public Health Nutr* 2000;3:473–485. [PubMed: 11276295]
14. Lamson DW, Brignall MS. Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. *Altern Med Rev* 1999;4:304–329. [PubMed: 10559547]
15. Liao PH, Chen SL, Shih HC, Chou MY. Induction of apoptosis in human oral cancer cell lines, OC2 and TSCCa, by chingwaysan. *Am J Chin Med* 2005;33:21–27. [PubMed: 15844830]
16. Liou CJ, Huang WC, Tseng J. Long-term oral administration of ginseng extract modulates humoral immune response and spleen cell functions. *Am J Chin Med* 2005;33:651–661. [PubMed: 16173538]
17. Liu CX, Xiao PG. Recent advances on ginseng research in China. *J Ethnopharmacol* 1992;36:27–38. [PubMed: 1501490]
18. Liu ZQ, Luo XY, Liu GZ, Chen YP, Wang ZC, Sun YX. In vitro study of the relationship between the structure of ginsenoside and its antioxidative or prooxidative activity in free radical induced hemolysis of human erythrocytes. *J Agric Food Chem* 2003;51:2555–2558. [PubMed: 12696936]
19. Mahmud A, Lavasanifar A. The effect of block copolymer structure on the internalization of polymeric micelles by human breast cancer cells. *Colloids Surf B Biointerfaces* 2005;45:82–89. [PubMed: 16144761]
20. Martin AR, Carides AD, Pearson JD, Horgan K, Elmer M, Schmidt C, Cai B, Chawla SP, Grunberg SM. Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. *Eur J Cancer* 2003;39:1395–1401. [PubMed: 12826042]
21. Mehendale S, Aung H, Wang A, Yin JJ, Wang CZ, Xie JT, Yuan CS. American ginseng berry extract and ginsenoside Re attenuate cisplatin-induced kaolin intake in rats. *Cancer Chemother Pharmacol* 2005;56:63–69. [PubMed: 15791456]
22. Ng TB, Liu F, Wang HX. The antioxidant effects of aqueous and organic extracts of *Panax quinquefolium*, *Panax notoginseng*, *Codonopsis pilosula*, *Pseudostellaria heterophylla* and *Glehnia littoralis*. *J Ethnopharmacol* 2004;93:285–288. [PubMed: 15234766]
23. Oh M, Choi YH, Choi S, Chung H, Kim K, Kim SI, Kim DK, Kim ND. Anti-proliferating effects of ginsenoside Rh2 on MCF-7 human breast cancer cells. *Int J Oncol* 1999;14:869–875. [PubMed: 10200336]
24. Ott MJ. Complementary and alternative therapies in cancer symptom management. *Cancer Pract* 2002;10:162–166. [PubMed: 11972571]
25. Raobaikady B, Purohit A, Chander SK, Woo LW, Leese MP, Potter BV, Reed MJ. Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate. *J Steroid Biochem Mol Biol* 2003;84:351–358. [PubMed: 12711022]
26. Satoh M, Kashiwara N, Fujimoto S, Horike H, Tokura T, Namikoshi T, Sasaki T, Makino H. A novel free radical scavenger, edarabone, protects against cisplatin-induced acute renal damage in vitro and in vivo. *J Pharmacol Exp Ther* 2003;305:1183–1190. [PubMed: 12649298]
27. Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. *Oncologist* 2003;8:187–198. [PubMed: 12697943]
28. Shao ZH, Xie JT, Vanden Hoek TL, Mehendale S, Aung H, Li CQ, Qin Y, Schumacker PT, Becker LB, Yuan CS. Antioxidant effects of American ginseng berry extract in cardiomyocytes exposed to acute oxidant stress. *Biochim Biophys Acta* 2004;1670:165–171. [PubMed: 14980443]
29. Sodhi A, Gupta P. Increased release of hydrogen peroxide (H₂O₂) and superoxide anion (O⁻²) by murine macrophages in vitro after cis-platin treatment. *Int J Immunopharmacol* 1986;8:709–714. [PubMed: 3023244]
30. Valli G, Giardina EG. Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. *J Am Coll Cardiol* 2002;39:1083–1095. [PubMed: 11923030]
31. Wang CZ, Wu JA, McEntee E, Yuan CS. Saponins composition in American ginseng leaf and berry assayed by high-performance liquid chromatography. *J Agric Food Chem* 2006;54:2261–2266. [PubMed: 16536605]

32. Wolfe SG, Chey WY, Washington MK, Harding J, Heath AT, McSorley DJ, Dukes GE, Hunt CM. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. *Am J Gastroenterol* 2001;96:803–811. [PubMed: 11280555]
33. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. *Cancer Res* 2004;64:1757–1764. [PubMed: 14996737]
34. Xie JT, Mehendale SR, Wang A, Han AH, Wu JA, Osinski J, Yuan CS. American ginseng leaf: ginsenoside analysis and hypoglycemic activity. *Pharmacol Res* 2004;49:113–117. [PubMed: 14643691]
35. Xie JT, McHendale S, Yuan CS. Ginseng and diabetes. *Am J Chin Med* 2005;33:397–404. [PubMed: 16047557]
36. Yokozawa T, Liu ZW. The role of ginsenoside-Rd in cisplatin-induced acute renal failure. *Renal Fail* 2000;22:115–127.
37. Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. *Trends Biochem Sci* 1995;20:435–439. [PubMed: 8533159]

Fig. 1. Chromatogram of American ginseng berry extract using HPLC analysis. Chromatographic conditions were described in Sect. 'Materials and methods'. The peaks of ginsenoside Rb1, Rb3, and Re are indicated. Chemical structures of these three ginsenosides are also shown

Fig. 2. Anti-proliferation effects of cisplatin and American ginseng berry extract on MCF-7 carcinoma cells after 72 h treatment. Control is normalized to 100%. **, $P < 0.01$, compared to control. *Cisp* cisplatin, *AGBE* American ginseng berry extract

Fig. 3. Additive effects of American ginseng berry extract on cisplatin's anti-proliferation activity in MCF-7 carcinoma cells. *, $P < 0.05$, compared to cisplatin alone. *Cisp* cisplatin, *AGBE* American ginseng berry extract

Fig. 4.

Effects of ginsenosides Rb1, Rb3, and Re on cisplatin's anti-proliferation activity in MCF-7 carcinoma cells. *, $P < 0.05$, and **, $P < 0.01$, compared to cisplatin alone. *Cisp* cisplatin